July 4, 2009
| Bio-IT World > Champions 2.0
Champions 2.0


March 12, 2007

Active Motif Inc.
Christopher Hoover

Christopher Hoover
Hoover
 
 active_motif-leon.jpg
Leon

TimeLogic Product Manager
Darryl Leon
AKS Product Manager

How has your company adapted and responded to the changing economic climate in the past five years when so many others companies did not?

As genomics became more mainstream, a broader range of scientists required tools to manipulate, search and compare sequence data. Active Motif’s TimeLogic team answered this demand with CodeQuest, a powerful biocomputing workstation that includes 1 or 2 FPGA-based accelerator cards and a suite of accelerated algorithms. Priced under $25,000 for academics, CodeQuest is the most affordable TimeLogic product ever released. It drives BLAST, Smith-Waterman, HMM, intron/exon mapping, and oligo searches with the performance of hundreds of CPUs, yet fits on your desk.

CodeQuest will soon be enhanced with PipeWorks, a visual interface that enables you to easily connect bioinformatics tools, filters and analysis steps without programming. This unique combination of intuitive workflow design and computing power will let any scientist build and execute complex bioinformatics analyses.

What is your vision for the future of the life sciences market over the next several years?

The life science market will always demand effective solutions for basic research, however the newly emerging diagnostics arena will require more customized tools and instruments — plus integrated high content assays, intuitive software and high-performance computing systems — to rapidly analyze data obtained from a variety of heterogeneous samples. Active Motif is building and acquiring technology in these domains to ensure that we can provide comprehensive, integrated solutions.

Partnerships are an effective way to track life science advances and ensure that your company delivers timely products and services. Which life sciences companies or organizations have you partnered with or invested in and why?

Active Motif’s focus on cell biology led to our partnership with Bioalma, a bioinformatics software company in Madrid, Spain. Bioalma develops AKS2, a knowledge mining system, which is designed for identifying novel relationships in the published literature that can support drug discovery research. The AKS2 system is marketed, distributed, and supported by Active Motif, and is an excellent complement to the TimeLogic biocomputing systems. As an example, once a collection of genes has been identified from a high-throughput sequence analysis workflow using CodeQuest, researchers can leverage AKS2’s advanced text-mining tools to explore how these genes are related to diseases, drugs, and other genes in the published literature.

What are your most exciting products and initiatives in development, and how will they improve life science research?

The TimeLogic biocomputing products dramatically extend our customers’ research computing budgets. For instance, our CodeQuest workstation costs less to acquire than the electricity required to power and cool a 64-CPU cluster for just 1 year. CodeQuest and our scalable DeCypher solutions deliver a strategic advantage in operational costs as well as search speed, usability and throughput.

We are excited to apply TimeLogic’s FPGA engineering expertise to next-generation sequencing initiatives. The combination of reduced sequencing cost and low-overhead computing makes intensive metagenomic projects — and ultimately the $1000 genome — much more feasible.

Where do you see your company in five years?

Active Motif will continue to develop both cell biology assays and biocomputing tools for disease-based research. By combining wetlab and computational tools into research workflows, our customers will be able to ask more holistic questions as they elucidate complex systems in biology.

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.





For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.